TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04873687

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External Counter Pulsation (ECP) therapy
Description: ECP therapy consist of 36 session, each session @1 hour/day, five days a week with initial pressure of 300mmHg
Study: NCT06543992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Administration of Thiotepa in Combination with Methotrexate via the Ommaya Reservoir
Description: Patients received intrathecal 15mg MTX combination with 10mg thiotepa twice a week for 2 weeks (4 injections) followed by monthly injections of 15mg MTX combination with 10mg thiotepa until an event that meets the criteria for termination occurs.
Study: NCT03155698

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: microneedling and Platelet rich plasma
Description: Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.~* After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: NB-UVB phototherapy
Description: All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
Study: NCT06055582

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Bread
Description: 81g (3 slices) harvest gold white bread as standard food.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Mango
Description: 250g of mango pulp of each mango variety was given to the subjects.
Study: NCT05301634

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: infraorbital block
Description: the patients will receive bilateral infraorbital block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: topical intranasal bupivacaine
Description: the patients will receive topical intranasal application of bupivacaine
Study: NCT05173636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical lateral glide
Description: A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical lateral glide
Description: A cervical segmental contralateral lateral glide treatment technique is performed at 1 or more motion segments of the cervical spine (C5-T1), including the level(s) of the segmental motion restriction. With the patient in a supine position, the therapist cradled the head and neck above, and including, the level to be treated and performed a lateral translatory movement away from the involved side while minimizing gross cervical side flexion or rotation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic mobilization technique
Description: Participants in group B will be given cervical lateral glide along with thoracic mobilization technique in prone position.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: thoracic mobilization technique
Description: Participants in group B will be given cervical lateral glide along with thoracic mobilization technique in prone position.
Study: NCT04854746

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-GI.1.NN
Description: GI.1 oral vaccine tablet

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-GI.1.NN
Description: GI.1 oral vaccine tablet

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VXA-GI.1.NN
Description: GI.1 oral vaccine tablet

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Tablets matching in number and appearance to active vaccine tablets

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Tablets matching in number and appearance to active vaccine tablets

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Tablets matching in number and appearance to active vaccine tablets
Study: NCT06508814

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower Insufflation Pressure
Description: Participants underwent laparoscopic hysterectomy with an insufflation pressure that is lower than the standard insufflation pressure used in this type of surgery.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Insufflation Pressure
Description: Participants underwent laparoscopic hysterectomy with a standard insufflation pressure.
Study: NCT04688788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a chimeric mouse/human monoclonal immunoglobulin gamma-1 (IgG1) antibody which depletes cluster of differentiation antigen 20 (CD20)-positive cells. Rituximab is approved for non-hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangitis and microscopic polyangitis, and pemphigus vulgaris.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab
Description: Ocrelizumab is a recombinant humanised monoclonal IgG1 antibody which depletes CD20-positive cells. Ocrelizumab is approved for multiple sclerosis.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fexofenadine
Description: Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexofenadine
Description: Premedication with oral fexofenadine 360 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Description: Premedication with oral. paracetamol 1000 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Premedication with oral methylprednisolone 100 mg is given before every infusion to reduce frequency and intensity of infusion related reactions.
Study: NCT05891327

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Maca
Description: 2.25 g Lepidium meyenii (Maca) extract twice per day for 12 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04307394

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifePlans
Description: LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge.
Study: NCT04948125

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: camrelizumab
Description: 200 mg intravenous (IV) camrelizumab on Day 1 and Day 15 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: 250 mg qd
Study: NCT06275399

Intervention type: DIAGNOSTIC_TEST
Intervention: OCT examination
Description: OCT examination for precise evaluation of plaque morphology within the coronary stenosis.

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood sampling
Description: Blood sampling directly from coronary artery (proximal and distal segment) arteries

Intervention type: DIAGNOSTIC_TEST
Intervention: Assessment of vFFR and shear stress parameters
Description: The procedure is based on non-invasive assessment of vFFR and shear stress parameters with dedicated software, deriving parameters directly from coronary angiography with the calculation based on the computational fluid dynamics
Study: NCT05356663

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: Medial glide MWM for knee flexion (supine) Lateral glide MWM for knee flexion (supine) Medial glide MWM for knee flexion.( prone ) Lateral glide MWM for knee flexion (prone)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hold Relax
Description: Hold-relax technique of PNF included, the affected knee will be flexed passively to the end of range with the therapist's hand on the patient's lower leg. Patients then performed 5 s of quadriceps contraction against the resistance of the therapist. Patients will be asked not to let move. At the end of 5 s, the patients will be asked to totally relax for 10 s and the therapist pushed the knee into more flexion and hold at that newly acquired range
Study: NCT06151925

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laminaria
Description: mechanical method for induction of labor

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laminaria
Description: mechanical method for induction of labor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaginal prostaglandin
Description: Vaginal prostaglandin for ripening

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vaginal prostaglandin
Description: Vaginal prostaglandin for ripening
Study: NCT06116383

Intervention type: DEVICE
Intervention: NIRS
Description: Renal perfusion will be evaluated with NIRS
Study: NCT06201091

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systematic simple swallowing training
Description: Systematic simple swallowing training includes the following:~Warm-up: including joint activities, chest expansion exercise, etc., totally 5 minutes.~Cognitive swallowing training: play video of food programs for five minutes. Lip training: Bounce the upper and lower lips to make a bo sound. 30-60 seconds.~Tongue training: Do the upper, lower, left, and right four-directional movements of the tongue muscle. 30-60 seconds.~Mandibular training: slowly open r mouth to the maximum, then slowly close it. 30-60 seconds.~Soft palate training: Make the sounds of g, k, and h for 1-2 minutes. Cheek puffing training: Close lips tightly and puff cheeks. 30-60 seconds. Swallowing training: We require the elderly to swallow small amounts of water intermittently and forcefully for 2-5 times.~Completing the above content in succession is called a round, and each training session includes 2-3 rounds. 2 sessions a day. Five days a week.
Study: NCT06024122

Intervention type: OTHER
Intervention: IRM exam
Description: A non-sedated MRI scan will be performed to assess the structure and function of the children's brains

Intervention type: OTHER
Intervention: IRM exam
Description: A non-sedated MRI scan will be performed to assess the structure and function of the children's brains
Study: NCT06241950

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: delandistrogene moxeparvovec
Description: Single IV infusion of delandistrogene moxeparvovec

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: imlifidase
Description: IV infusion of Imlifidase
Study: NCT01456923

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment with chemotherapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Only chemotherapy treatment for study cohort
Description: Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Study: NCT06280677

Intervention type: OTHER
Intervention: AURORA-Donor
Description: Explorative study of cumulus cells gene expression in relation to the oocyte competence for good quality blastocyst formation and predictive for clinical pregnancy.

Intervention type: OTHER
Intervention: AURORA-Donor
Description: Explorative study of cumulus cells gene expression in relation to the oocyte competence for good quality blastocyst formation and predictive for clinical pregnancy.
Study: NCT04051801

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of VU319
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose Escalation of Placebo
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose Escalation of Placebo
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose Escalation of Placebo
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of Placebo
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of Placebo
Description: dose levels of the cohorts will be increased step wise

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Escalation of Placebo
Description: dose levels of the cohorts will be increased step wise
Study: NCT05268289

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iptacopan (part 1)
Description: Taken for 52 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iptacopan (part 2)
Description: Taken for 52 Weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + standard of care
Description: Taken for 52 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + standard of care
Description: Taken for 52 Weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iptacopan + placebo
Description: Taken for 52 Weeks
Study: NCT04918121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yutiq 0.18 MG Drug Implant
Description: a sustained-release steroid insert (Yutiq)
Study: NCT06136858

Intervention type: DEVICE
Intervention: Cuirass ventilation
Description: We will fit the Cuirass Shell and start Biphasic Cuirass Ventilation on all participants.
Study: NCT06066879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine Hydrochloride
Description: Pre-Operative Ketamine infusion
Study: NCT05718102

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Population-health management
Description: Population-health management

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Population-health management
Description: Population-health management
Study: NCT05879133

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Survey

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit Bit
Description: measures physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fit Bit
Description: measures physical activity
Study: NCT05666089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: intracanal medication of NAC with concentration 1 gm/ml in the form of a paste

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium hydroxide
Description: intracanal medication of calcium hydroxide paste (metapaste)
Study: NCT04920929

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hydrophilic Biomaterial
Description: PICC made out of a Hydrophilic Biomaterial

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermoplastic Polyurethane
Description: PICC made out of a thermoplastic polyurethane material
Study: NCT04799314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 Inhibitor Tislelizumab maintenance therapy
Description: PD-1 Inhibitor Tislelizumab maintenance therapy
Study: NCT05749887

Intervention type: PROCEDURE
Group type: OTHER
Intervention: salvage surgery
Description: Open/minimally invasive salvage surgery performed when cervical biopsy and/or PET/CT scan ( SUVmax ≥2.5 ) indicate patients with residual tumor intrapelvic 4-12 weeks after standard CCRT.~Surgery type:~1. No parametrial involvement, extrafascial hysterectomy;~2. There is parametrial involvement, extensive hysterectomy(Q-MC);~3. Only bladder invasion, anterior pelvic exenteration;~4. Only rectal invasion, posterior pelvic exenteration or total pelvic exenteration;~5. Invasion of bladder and rectum, total exenteration.~6. The pelvic lymph nodes are removed at the same time when 18F -FDG PET /CT indicates that the SUVmax is ≥ 2.5.
Study: NCT05875597

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy exercise programme
Description: Carrying out a programme of therapeutic physical exercise for 12 weeks, twice a week for 45 minutes.
Study: NCT06502262

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: patient will be given 3ml (15mg) of 0.5% hyperbaric bupivacaine + 0.5 ml of normal saline intrathecally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: patient will be given 3ml (15mg) of 0.5% hyperbaric bupivacaine + 0.5 ml of normal saline intrathecally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine Hydrochloride
Description: patient will be given 3ml (15mg) of 0.5% hyperbaric bupivacaine + 0.5 ml of normal saline intrathecally.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: patients will be given 3ml (15mg) of 0.5%hyperbaric bupivacaine +0.5ml (25 microgram) of fentanyl intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: patients will be given 3ml (15mg) of 0.5%hyperbaric bupivacaine +0.5ml (25 microgram) of fentanyl intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: patients will be given 3ml (15mg) of 0.5%hyperbaric bupivacaine +0.5ml (25 microgram) of fentanyl intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patient will receive 3ml (15mg) of .05 hyperbaric bupivacaine 0.5ml(5 microgram) of diluted dexmedetomidine intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patient will receive 3ml (15mg) of .05 hyperbaric bupivacaine 0.5ml(5 microgram) of diluted dexmedetomidine intrathecally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: patient will receive 3ml (15mg) of .05 hyperbaric bupivacaine 0.5ml(5 microgram) of diluted dexmedetomidine intrathecally
Study: NCT05655845

Intervention type: OTHER
Intervention: bowel function score(BFS) questionnaire survey
Description: A cross-sectional bowel function score(BFS) questionnaire survey was conducted in patients with HD who underwent PTs between January 2014 and December 2019 at Children's Hospital of Nanjing Medical University.Patients consented to the survey were asked to complete the questionnaire,and were divided into two groups: dysfunction group(BFS\<17 ); and normal group (BFS\>=17 ). The operative age, birth weight, premature delivery status, operative weight, aganglionic segment, single or stage PT, surgical approach(laparotomy or laparoscopy), post-operative Hirschsprung-associated enterocolitis (HAEC),and immediate complications were recorded and compared between two groups。Both univariate and multivariate regression analysis were used to seek the risk factors of bowel dysfunction after PTs in HD. .

Intervention type: OTHER
Intervention: bowel function score(BFS) questionnaire survey
Description: A cross-sectional bowel function score(BFS) questionnaire survey was conducted in patients with HD who underwent PTs between January 2014 and December 2019 at Children's Hospital of Nanjing Medical University.Patients consented to the survey were asked to complete the questionnaire,and were divided into two groups: dysfunction group(BFS\<17 ); and normal group (BFS\>=17 ). The operative age, birth weight, premature delivery status, operative weight, aganglionic segment, single or stage PT, surgical approach(laparotomy or laparoscopy), post-operative Hirschsprung-associated enterocolitis (HAEC),and immediate complications were recorded and compared between two groups。Both univariate and multivariate regression analysis were used to seek the risk factors of bowel dysfunction after PTs in HD. .
Study: NCT04671368

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Artificial Intelligence
Description: The investigators will use the Artificial Intelligence Diagnostic System to review the H＆E stained slide of each patient and then report the classification of the tumor on a 10-type scale.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Practicing Pathologists
Description: The ordinary pathologist will review the H＆E stained slide of each patient(without additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale only bases on the slide images

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Gold Standard
Description: Firstly, the two expert pathologist(\>=10 years of experience) will review the H＆E stained slide of each patient on their own (with additional informations such as: Immunohistochemistry et al.) and then report the classification of the tumor on a 10-type scale.If they report the same opinion, that opinion will perform as the ground truth; while if their opinion clash with each other, the expert pathologist(\>=15 years of experience) will get involved and the agreement of three experts will perform as the ground truth
Study: NCT04791527

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mind-body therapy
Description: Online yoga, meditation, behavior change tips, and nutrition tips
Study: NCT05438901

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: leech therapy
Description: effects of medicinal leeches